- Home
- SATL vs MRVI Comparison
SATL vs MRVI Comparison
Compare SATL & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- MRVI
- Stock Information
- Founded
- SATL 2010
- MRVI 2014
- Country
- SATL United States
- MRVI United States
- Employees
- SATL N/A
- MRVI N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- MRVI Health Care
- Exchange
- SATL Nasdaq
- MRVI Nasdaq
- Market Cap
- SATL 373.7M
- MRVI 376.2M
- IPO Year
- SATL N/A
- MRVI 2020
- Fundamental
- Price
- SATL $3.53
- MRVI $2.81
- Analyst Decision
- SATL
- MRVI Hold
- Analyst Count
- SATL 0
- MRVI 9
- Target Price
- SATL N/A
- MRVI $5.25
- AVG Volume (30 Days)
- SATL 1.7M
- MRVI 940.3K
- Earning Date
- SATL 11-12-2025
- MRVI 11-06-2025
- Dividend Yield
- SATL N/A
- MRVI N/A
- EPS Growth
- SATL N/A
- MRVI N/A
- EPS
- SATL N/A
- MRVI N/A
- Revenue
- SATL $13,868,000.00
- MRVI $219,830,000.00
- Revenue This Year
- SATL N/A
- MRVI N/A
- Revenue Next Year
- SATL N/A
- MRVI $7.23
- P/E Ratio
- SATL N/A
- MRVI N/A
- Revenue Growth
- SATL 1.09
- MRVI N/A
- 52 Week Low
- SATL $0.93
- MRVI $1.67
- 52 Week High
- SATL $5.49
- MRVI $9.50
- Technical
- Relative Strength Index (RSI)
- SATL 47.34
- MRVI 60.20
- Support Level
- SATL $3.35
- MRVI $2.61
- Resistance Level
- SATL $4.12
- MRVI $2.80
- Average True Range (ATR)
- SATL 0.24
- MRVI 0.16
- MACD
- SATL 0.00
- MRVI 0.04
- Stochastic Oscillator
- SATL 23.38
- MRVI 76.09
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.